A recent survey on the performance of publicly listed Korean health care firms in 2023 unveiled a still floundering med-tech sector, although local pharmaceutical companies seemed to rebound after the COVID-19 pandemic.
A recent survey on the performance of publicly listed Korean health care firms in 2023 unveiled a still floundering med-tech sector, although local pharmaceutical companies seemed to rebound after the COVID-19 pandemic.
One of the side effects of COVID-19 is the acceleration of a shift in health care delivery that is changing how drug and device companies market their products to doctors. There’s no going back to the commercial model where having a sales rep call on a doctor was the way to market a product, Rita Numerof, CEO and co-founder of Numerof & Associates, said during a Jan. 21 webinar on the impact the pandemic has had on drug and device detailing.
Growing sales of its multiple sclerosis (MS) therapies and lower R&D expenses led Biogen Inc. to beat both top- and bottom-line expectations during the second quarter, despite lower-than-expected sales of its spinal muscular atrophy (SMA) drug, Spinraza (nusinersen).